A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

Archive ouverte

Fenwarth, Laurene | Thomas, Xavier | Botton, Stephane, De | Duployez, Nicolas | Bourhis, Jean-Henri | Lesieur, Auriane | Fortin, Gael | Meslin, Paul-Arthur | Yakoub-Agha, Ibrahim | Sujobert, Pierre | Dumas, Pierre-Yves | Recher, Christian | Lebon, Delphine | Berthon, Celine | Michallet, Mauricette | Pigneux, Arnaud | Nguyen, Stephanie | Chantepie, Sylvain | Vey, Norbert | Raffoux, Emmanuel | Celli-Lebras, Karine | Gardin, Claude | Lambert, Juliette | Malfuson, Jean-Valere | Caillot, Denis | Maury, Sebastien | Ducourneau, Benoit | Turlure, Pascal | Lemasle, Emilie | Pautas, Cecile | Chevret, Sylvie | Terre, Christine | Boissel, Nicolas | Socie, Gerard | Dombret, Herve | Preudhomme, Claude | Itzykson, Raphael

Edité par CCSD ; American Society of Hematology -

International audience. A multistage model instructed by a large dataset (knowledge bank [KB] algorithm) has recently been developed to improve outcome predictions and tailor therapeutic decisions, including hematopoietic stem cell transplantation (HSCT) in acute myeloid leukemia (AML). We assessed the performance of the KB in guiding HSCT decisions in first complete remission (CR1) in 656 AML patients younger than 60 years from the ALFA-0702 trial (NCT00932412). KB predictions of overall survival (OS) were superior to those of European LeukemiaNet (ELN) 2017 risk stratification (C-index, 68.9 vs 63.0). Among patients reaching CR1, HSCT in CR1, as a time-dependent covariate, was detrimental in those with favorable ELN 2017 risk and those with negative NPM1 minimal residual disease (MRD; interaction tests, P = .01 and P = .02, respectively). Using KB simulations of survival at 5 years in a scenario without HSCT in CR1 (KB score), we identified, in a similar time-dependent analysis, a significant interaction between KB score and HSCT, with HSCT in CR1 being detrimental only in patients with a good prognosis based on KB simulations (KB score >= 40; interaction test, P = .01). We could finally integrate ELN 2017, NPM1 MRD, and KB scores to sort 545 CR1 patients into 278 (51.0%) HSCT candidates and 267 (49.0%) chemotherapy-only candidates. In both time-dependent and 6-month landmark analyses, HSCT significantly improved OS in HSCT candidates, whereas it significantly shortened OS in chemotherapy-only candidates. Integrating KB predictions with ELN 2017 and MRD may thus represent a promising approach to optimize HSCT timing in younger AML patients.

Consulter en ligne

Suggestions

Du même auteur

Prognostic significance of concurrent gene mutations i n intensively treated patients with IDH-mutated AML: an ALFA study

Archive ouverte | Duchmann, Matthieu | CCSD

International audience. In patients with isocitrate dehydrogenase (IDH)-mutated acute myeloid leukemia (AML) treated by intensive chemotherapy (IC), prognostic significance of co-occurring genetic alterations and al...

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

Archive ouverte | Malfuson, Jean Valere | CCSD

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL, DEC 07-10, 2019. International audience

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Archive ouverte | Itzykson, Raphael | CCSD

International audience. To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) >= 60 years of age treated with 7+3, we sequenced 37 genes in...

Chargement des enrichissements...